Compass Therapeutics to Present at J.P. Morgan Healthcare Conference

Compass Therapeutics to Present at J.P. Morgan Healthcare Conference

Jan. 3, 2019 by

CAMBRIDGE, Mass., January 3, 2019 — Compass Therapeutics, a biotechnology company committed to the ambitious goal of comprehensively drugging the human immune system, will discuss its novel approach to antibody

Compass Therapeutics Expands Leadership Team with Appointments of Chief Medical Officer and Chief Financial Officer

Compass Therapeutics Expands Leadership Team with Appointments of Chief Medical Officer and Chief Financial Officer

Dec. 19, 2018 by

CAMBRIDGE, Mass. Dec. 19, 2018 — Compass Therapeutics, a biotechnology company committed to the ambitious goal of comprehensively drugging the human immune system, today announced the appointment of veteran biopharma

Compass Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference

Compass Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference

Nov. 26, 2018 by

CAMBRIDGE, Mass., Nov. 26, 2018 — Compass Therapeutics, a biotechnology company committed to the ambitious goal of comprehensively drugging the human immune system, today announced that Thomas Schuetz, M.D., Ph.D.,

Compass Therapeutics Announces Preclinical Data on Lead Antibody Program and NK Cell Engager Platform to be Presented at the Society for Immunotherapy of Cancer Annual Meeting

Compass Therapeutics Announces Preclinical Data on Lead Antibody Program and NK Cell Engager Platform to be Presented at the Society for Immunotherapy of Cancer Annual Meeting

Nov. 6, 2018 by

CAMBRIDGE, Mass., Nov. 6, 2018 — Compass Therapeutics, a biotechnology company committed to the ambitious goal of comprehensively drugging the human immune system, today announced that preclinical data on CTX-471,

FierceBiotech Names Compass Therapeutics a 2018 “Fierce 15” Biotech Company

FierceBiotech Names Compass Therapeutics a 2018 “Fierce 15” Biotech Company

Oct. 2, 2018 by

CAMBRIDGE, Mass., Oct 2, 2018 — Compass Therapeutics, a biotechnology company committed to the ambitious goal of comprehensively drugging the human immune system, today announced that it has been named

Compass Therapeutics Completes $132 Million Series A Financing to Advance Next-Generation Antibody-Based Therapeutics into the Clinic

Compass Therapeutics Completes $132 Million Series A Financing to Advance Next-Generation Antibody-Based Therapeutics into the Clinic

Jul. 12, 2018 by

This is the excerpt for your very first post.